Alnylam Pharmaceuticals (ALNY) Announces Earnings Results

Alnylam Pharmaceuticals (NASDAQ:ALNY) posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10), Bloomberg Earnings reports. The business had revenue of $37.90 million for the quarter, compared to analysts’ expectations of $19.31 million. Alnylam Pharmaceuticals had a negative return on equity of 48.88% and a negative net margin of 545.95%. The business’s quarterly revenue was up 116.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.32) earnings per share.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up $0.72 on Thursday, hitting $119.98. The company had a trading volume of 498,500 shares, compared to its average volume of 884,270. The firm has a market capitalization of $11,890.22, a price-to-earnings ratio of -22.18 and a beta of 2.69. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a fifty-two week low of $45.00 and a fifty-two week high of $147.63.

A number of brokerages have recently commented on ALNY. BMO Capital Markets dropped their price objective on shares of Alnylam Pharmaceuticals from $165.00 to $160.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. Jefferies Group set a $156.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 9th. Nomura lifted their price target on shares of Alnylam Pharmaceuticals to $86.00 and gave the company a “sell” rating in a research note on Friday, February 9th. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $128.00 to $118.00 and set an “equal weight” rating on the stock in a research note on Friday, February 9th. Finally, Credit Suisse Group set a $151.00 price objective on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 9th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $126.98.

In related news, CEO John Maraganore sold 73,415 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $130.90, for a total transaction of $9,610,023.50. Following the sale, the chief executive officer now directly owns 223,125 shares in the company, valued at approximately $29,207,062.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Laurie Keating sold 30,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $135.89, for a total value of $4,076,700.00. Following the sale, the senior vice president now owns 41,500 shares in the company, valued at $5,639,435. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 146,409 shares of company stock worth $19,279,377. Company insiders own 4.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Verition Fund Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $1,060,000. Gotham Asset Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $772,000. Bradley Foster & Sargent Inc. CT lifted its holdings in shares of Alnylam Pharmaceuticals by 100.1% in the 3rd quarter. Bradley Foster & Sargent Inc. CT now owns 8,235 shares of the biopharmaceutical company’s stock worth $968,000 after purchasing an additional 4,120 shares during the last quarter. WINTON GROUP Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $10,633,000. Finally, First Trust Advisors LP lifted its holdings in shares of Alnylam Pharmaceuticals by 25.3% in the 3rd quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock worth $92,185,000 after purchasing an additional 158,288 shares during the last quarter. Hedge funds and other institutional investors own 88.59% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Alnylam Pharmaceuticals (ALNY) Announces Earnings Results” was first published by Week Herald and is owned by of Week Herald. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://weekherald.com/2018/02/15/alnylam-pharmaceuticals-alny-issues-earnings-results.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply